Insulin in Medical Technology

TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men

... of six months. The study found that GH caused insulin resistance (the body's inability to respond to and use the insulin it produces) to increase, yet it had a beneficial ... on glucose tolerance, elevated cholesterol and insulin sensitivity--changes in older adults that occur ...

Diabetes Gene Raises Odds of Lower Birth Weight

... either when the pancreas produces too little insulin or when the body cannot efficiently use the insulin that is produced. Formerly called adult-onset ... -- a finding that supports the so-called fetal insulin hypothesis. Previous studies by European diabetes ...

5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH

... (insulin glargine [rDNA] injection) versus NPH insulin on progression of retinopathy in patients with ... the longest controlled study ever reported using insulin glargine. Diabetic retinopathy is a major ... mitogenic effects different from the human NPH insulin within the eye. "This 5-year study is the ...

Spherix Announces Positive Phase 2 Study Results

... tagatose load (75 g) caused no increase in plasma insulin or glucose concentrations in either healthy or ... by elevated blood glucose in the context of insulin resistance and comparative insulin deficiency. While T2DM is often initially managed ...

MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes

... PROTEGE includes both the patient's total daily insulin usage and his/her HbA1c levels at 12 months. ... the pancreas, patients may require less injected insulin and their blood glucose levels may be easier to ... suddenly and leave a person dependent on injected insulin for life. The disease carries the constant threat ...

Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions

... Secondary improvements in glucose tolerance and insulin sensitivity Significant reduction in ... 4 (RBP4) caused significant improvements in insulin sensitivity with associated improvement in ... of antisense drugs to significantly improve insulin sensitivity in diabetic animals, Isis also ...

Studies Show AFRESA(R) Controls Post-Meal Sugar Levels With Less Weight Gain and Hypoglycemia Risk for Diabetes Patients

... Latest data on ultra rapid acting insulin presented at the American Diabetes Association's ... show that the investigational ultra rapid acting insulin AFRESA(R) (insulin human [rDNA origin]) Inhalation Powder combined with basal insulin is comparable to standard of care therapies in ...

New Study Showed Lantus(R) Plus One, Two or Three Shots of Apidra(R) Lowered Patients' Blood Sugar

... "Effects of 1, 2, or 3 Prandial Injections of insulin Glulisine on Glycemic Control in Type 2 Diabetes Patients on insulin Glargine and Oral Drugs," evaluating patients adding prandial insulin Apidra(R) (insulin glulisine [rDNA origin] ...

Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk

... Glycemic Parameters: fasting glucose, fasting insulin and insulin resistance Inflammatory Markers of ... in serum lipids, markers of inflammation and insulin resistance, and in the BLOOM-DM trial, other ...

AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA

... investigational product comparable to standard insulin therapy in pulmonary function tests NEW ... Powder is a well-tolerated, ultra rapid acting insulin with changes in pulmonary function tests ... with AFRESA and those treated with standard insulin therapy. "Current ...

Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines

... improve blood sugar control by directly targeting insulin resistance, an underlying cause of type 2 ... adults with type 2 diabetes. Taking AVANDIA with insulin or nitrates is not recommended. ... of heart disease or stroke Take insulin or nitrate medicines Have a type of ...

Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe

... targets the core defects of type 2 diabetes - insulin resistance (when the body does not efficiently use the insulin it produces) and insulin deficiency (when the body does not produce enough ...

InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting

... of INT131 to safely and effectively address insulin resistance in a presentation entitled "INT131: ... About INT131 INT131 is a next-generation insulin sensitizer currently in Phase 2b testing that addresses insulin resistance, a key etiological feature in the ...

Juvenile Diabetes Research Foundation to Honor Duane DeSisto of Insulet Corporation and Senator Edward M. Kennedy at 27th Annual Hearts & Heroes Gala

... of people with diabetes. The company's OmniPod insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use ... System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent ...

Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial

... Results show improved insulin sensitivity and lower glucose levels without ... that its lead compound, MSDC-0160, can improve insulin sensitivity and lower blood glucose levels in ... thiazolidinedione (TZD) can improve insulin sensitivity and lower glucose similar to a ...

Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)

... (PK) and Pharmacodynamics (PD) of Oral insulin Formulations in Subjects with Type 2 Diabetes ... the study, the trial demonstrated that the oral insulin capsule had a good safety profile and was well ... 434-P Clinical Therapeutics/New Technology - insulin Delivery Systems and is available for viewing ...

Pioneering Diamyd(R) Study to Prevent Childhood Diabetes Approved

... autoimmune disease process that destroys their insulin producing cells. If vaccination with ... in the disease process before too many of the insulin cells are destroyed, the disease will be ... symptoms and would not become dependent on insulin injections for survival, which otherwise ...

MannKind Updates Status of NDA Submission for AFRESA

... ("NDA") for AFRESA(R), an ultra rapid-acting insulin that has completed Phase 3 clinical trials. As ... AFRESA(R) AFRESA is an ultra rapid acting insulin product that has completed Phase 3 trials. The ... profile of AFRESA sets it apart from all other insulin products. The large surface area of the lung ...

Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository

... a proof of concept study in South Africa of insulin suppositories, ORMD-0802, using its proprietary ... with two different formulations. The insulin suppositories showed rapid insulin absorption and reactive glucose lowering effect. ...

MannKind Reports Successful Completion of Device Bioequivalence Trial

... deliver AFRESA(TM), MannKind's ultra rapid acting insulin that recently completed Phase 3 clinical trials. ... AFRESA AFRESA is an ultra rapid acting insulin product that has completed Phase 3 trials. The ... profile of AFRESA sets it apart from all other insulin products. The large surface area of the lung ...

MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes

... the company's ultra rapid acting, inhaled insulin product, at 9 a.m. Eastern Time on Thursday, ... Afresa is an ultra rapid acting inhaled insulin product that has completed Phase 3 trials. The ... profile of Afresa sets it apart from all other insulin products. The large surface area of the lung ...

Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals

... by Arena and has the potential to stimulate insulin release in response to increases in blood ... cells in the pancreas responsible for producing insulin in response to increases in blood glucose. The ... the GDIR is intended to more efficiently promote insulin release by beta cells in response to elevated ...

Overweight Siblings of Children With Type 2 Diabetes Likely to Have Abnormal Blood Sugar Levels

... investigators found no significant differences in insulin resistance, as measured by the homeostasis model ... activity, race/ethnicity, family history and insulin resistance. Obesity decreases insulin sensitivity, as does puberty, when all ...

Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics

... works centrally and peripherally to regulate insulin and leptin pathways through the highly selective ... population, including oral glucose tolerance and insulin sensitivity, satiety and weight loss. ... produced dose-dependent weight loss and improved insulin sensitivity. We expect the multiple dose data ...

FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes

... control study of Apidra(R) in comparison with insulin lispro, in 572 children and adolescents (4 ... or basal insulin. Apidra(R) can also be used in insulin infusion pump therapy for blood sugar control. ... with type 1 diabetes. Study patients received insulin glulisine or lispro 0-15 minutes premeal. These ...

Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository

... October 23 /PRNewswire-FirstCall/ -- - An insulin Suppository Represents an Important Development ... for ORMD 0802, the company's newly developed insulin suppository. Oramed's Phase 1A trials on its insulin suppository mark an important step in the history ...

Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting

... that controls the function of both the leptin and insulin pathways to normalize glucose and ... secondary outcomes of oral glucose tolerance and insulin sensitivity, satiety and weight loss. About ... controlling the function of both the leptin and insulin pathways. By inhibiting PTP1B, MSI-1436 ...

Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society

... type 1 and type 2 diabetes who use mealtime insulin and who have failed to achieve desired glucose control despite optimal insulin therapy. Since launch, over 110,000 patients have ... all patients with diabetes. SYMLIN is used with insulin and has been associated with an increased risk ...

Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics

... Assess the Safety and Efficacy of ORMD 0801, Oral insulin Capsule, on Type 1 ... commenced Phase 2A studies of ORMD 0801, its oral insulin capsule, on Type 1 diabetics at the Hadassah ... on assessing the safety and efficacy of its oral insulin capsule on nine Type 1 diabetes patients. The ...

Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes

... primarily by stimulating glucose-dependent insulin secretion. In addition, GLP-1 suppresses ... medications. ACTOS is a TZD that directly targets insulin resistance, a condition in which the body does not efficiently use the insulin it produces to control blood glucose levels. ...

MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes

... to a rapid-acting insulin analog VALENCIA, Calif., Sept. 16 ... Phase 3 clinical study of the Technosphere(R) insulin System in patients with type 1 diabetes (Study ... of prandial inhalations of Technosphere insulin (the TI group) versus prandial subcutaneous ...

Modified Insulin Most Effective For Controlling Post-Meal Blood Sugar Levels

... appears to be equally effective as pre-mixed insulin analogues for lowering blood sugar levels when ... decisions. "While it is clear that pre-mixed insulin analogues offer certain advantages to patients ... carefully with their physician." Pre-mixed insulin analogues are a modified form of ...

Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin

... produced greater A1C reductions versus pre-mixed insulin in people with type 2 diabetes. Both studies, ... basal-bolus therapy when compared to pre-mixed insulin regimens. Basal-bolus insulin regimens that combine once-daily LANTUS(R) as ...

Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes

... parameters (HOMA, C-peptide and proinsulin to insulin ratio), was also significantly improved ... Liraglutide works by stimulating the release of insulin only when glucose levels become too high and by ... the most advanced products within the area of insulin delivery systems. In addition to diabetes care, ...

Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)

... (PK) and Pharmacodynamics (PD) of Five Oral insulin Formulations in Healthy Subjects," has been ... highlighting the successful results from its oral insulin trials on healthy volunteers. Oramed's poster ... patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. ...

Study Shows Benefits of a High Omega-3 Diet in Older Adults

... High Omega-3 Fat Intake Improves insulin Sensitivity and Reduces Inflammatory Markers, But ... found that a diet high in omega-3 fat improves insulin sensitivity and reduces inflammatory markers, but ... concluded that a diet high in omega-3 increases insulin sensitivity and reduces inflammatory markers," ...

Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market

... insulins and neutral protamine Hagedorn (NPH) insulin to more-expensive rapid-acting insulin analogues and long-acting insulin analogues. Short-acting insulin analogues provide a more rapid onset of action ...

New Survey Explores the Impact of Insulin Injections and Communications Between Patients and Healthcare Providers

... between people with diabetes that require insulin injections and their healthcare providers. ... have experienced some level of dread relating to insulin injections (eight percent strongly ... of individuals surveyed felt that injecting insulin was the hardest aspect of their diabetes care ...

Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule

... of the ORMD 0801- Oral insulin Capsule JERUSALEM, Israel, August 6 ... results from the clinical trial of its oral insulin capsule, ORMD 0801. The trial demonstrated ... patented flagship product, an orally ingestible insulin capsule currently in phase 2 clinical trials. ...

Treatment Corrects Severe Insulin Imbalance in Animal Studies

... genetically engineered to have abnormally high insulin levels. If this approach succeeds in humans, it ... potentially devastating genetic disease in which insulin levels become dangerously high. "There is ... the insulin-secreting beta cells in the pancreas. insulin levels rage out of control and severely reduce ...